Für die Vergleichbarkeit klinischer Studien ist eine international einheitliche Lymphom-Klassifikation
von grundlegender Bedeutung. Aktuell gibt es 2 parallele Klassifikationen: die „International
Consensus Classification“ und die WHO-Klassifikation. Neben vielen Gemeinsamkeiten
gibt es auch einige Unterschiede, wobei die traditionelle Unterteilung in indolente
und aggressive B-Zell-Lymphome, Hodgkin-Lymphome und T-Zell-Lymphome weiter besteht.
Abstract
An internationally uniform lymphoma classification is of fundamental importance for
the comparability of clinical studies. There are currently 2 parallel classifications:
the “International Consensus Classification” and the WHO-classification. Follicular
lymphoma 3B is classified separately as follicular large cell lymphoma in WHO-HAEM5.
The diagnostic criteria of lymphoplasmocytic lymphoma (LPL) have been adjusted, both
classifications recommend molecular testing for MYD88 and CXCR4 mutations. There are
no significant diagnostic changes in aggressive B-cell lymphomas. The ICC classify
NLPBL and THRLBCL into the group of large B-cell lymphomas (LBCL). NLPHL/NLPBL-specific
therapy must be considered, which differs greatly from the therapy of DLBCL, especially
in the early stages. Peripheral T-cell lymphomas are a group of nodal T-cell lymphomas
with a TFH phenotype and frequent mutations; peripheral T-cell lymphoma (NOS) is therefore
a diagnosis of exclusion. Indolent T-cell lymphomas/lymphoproliferations of the GI
tract are rare but must be differentiated from aggressive T-cell lymphomas. The WHO-HAEM5
also includes reactive/non-neoplastic lymph node lesions classified according to B
or T cell predominance.
Schlüsselwörter
Klassifikation - International Consensus Classification - WHO - B-Zell-Lymphom - Hodgkin-Lymphom
- T-Zell-Lymphom
Keywords
classification - International Consensus Classification - WHO - B-cell lymphoma -
Hodgkin lymphoma - T-cell lymphoma
